Treatment with adalimumab in patients with chronic inflammatory rheumatic diseases
- \(\bf Background:\) Previous experiences with non-medical switching of adalimumab (ADA) in patients with chronic inflammatory rheumatic diseases (CIRD) come mainly from phase III extension of randomised clinical trials and little from routine care. \(\bf Objectives:\) To analyse treatment trajectories over 2 years in patients with CIRD conducting a non-medical switch from originator to biosimilar ADA. \(\bf Design:\) A retrospective observational cohort study was conducted with data from a third-level rheumatology centre in Germany. CIRD patients on originator ADA who switched to ADA biosimilar from October 2018 onwards were identified and followed until September 2020. \(\bf Methods:\) Patients’ characteristics were compared between the four \(\textit {a priori}\) defined treatment trajectories "continued biosimilar ADA therapy", "back-switch to originator ADA therapy", "switch to another biological disease-modifying anti-rheumatic drug (bDMARD) therapy" and "stopped bDMARD therapy/death/drop out". Factors associated with continuing biosimilar ADA therapy were analysed using Cox proportional hazards regression analyses. \(\bf Results:\) A total of 121 CIRD patients were included. Most patients (66.9%) continued therapy with biosimilar ADA over 2 years, with a treatment retention rate of 73.1%. Whereas 21 patients (17.4%) switched back to originator ADA, mainly due to adverse events, and 8 patients (6.6%) switched to a different bDMARD, mainly due to lack of effect. The estimated risk of withdrawal was lower for longer prior duration on originator ADA [hazard ratio (HR): 0.82; 95% CI: 0.69–0.97] and higher for higher C-reactive protein levels at baseline (HR: 1.18; 95% CI: 1.00–1.39). Male patients, older patients and those for whom originator ADA was their first bDMARD tended to have a lower risk of withdrawal. \(\bf Conclusion:\) Our results indicated that three of four patients continue biosimilar ADA over 2 years with lower risks of withdrawal for male sex, older age, longer prior duration on originator ADA and originator ADA as first bDMARD.
Author: | Imke RedekerORCiDGND, Stefan MoustakisGND, Styliani TsiamiORCiDGND, Xenofon BaraliakosORCiDGND, Ioana AndreicaORCiDGND, Björn BühringGND, Jürgen BraunORCiDGND, Uta KiltzORCiDGND |
---|---|
URN: | urn:nbn:de:hbz:294-110018 |
DOI: | https://doi.org/10.1177/1759720X231197087 |
Parent Title (English): | Therapeutic advances in musculoskeletal disease |
Subtitle (English): | a study of treatment trajectories on a patient level in routine care |
Publisher: | Sage Publications LtD |
Place of publication: | Thousand Oaks, Kalifornien, Vereinigte Staaten |
Document Type: | Article |
Language: | English |
Date of Publication (online): | 2024/03/04 |
Date of first Publication: | 2023/09/08 |
Publishing Institution: | Ruhr-Universität Bochum, Universitätsbibliothek |
Tag: | Open Access Fonds adalimumab; chronic inflammatory rheumatic diseases; treatment trajectories |
Volume: | 15 |
First Page: | 1 |
Last Page: | 12 |
Note: | Article Processing Charge funded by the Deutsche Forschungsgemeinschaft (DFG) and the Open Access Publication Fund of Ruhr-Universität Bochum. |
Institutes/Facilities: | Rheumazentrum Ruhrgebiet |
Dewey Decimal Classification: | Technik, Medizin, angewandte Wissenschaften / Medizin, Gesundheit |
open_access (DINI-Set): | open_access |
Licence (English): | Creative Commons - CC BY-NC 4.0 - Attribution-NonCommercial 4.0 International |